Evidence map›Paper›PMID 42398146›Full record

ArticleClinics (Sao Paulo, Brazil)2026

Symptom, functional, and medication overlap between long COVID and fibromyalgia.

Kevin V Hackshaw, Michelle M Osuna-Diaz, Katherine R Sebastian, Shreya Madhav Nuguri, Silvia de Lamo Castellvi, Lianbo Yu, Zhanna Mikulik, M Monica Giusti, William Michael Brode, Luis Rodriguez-Saona

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinics (Sao Paulo, Brazil), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Kevin V HackshawDepartment of Internal Medicine, Division of Rheumatology, Dell Medical School, The University of Texas, Austin, USA. Electronic address: kevin.hackshaw@austin.utexas.edu.
Michelle M Osuna-DiazDepartment of Internal Medicine, Dell Medical School, The University of Texas, Austin, USA.
Katherine R SebastianDepartment of Internal Medicine, Dell Medical School, The University of Texas, Austin, USA.
Shreya Madhav NuguriDepartment of Internal Medicine, Dell Medical School, The University of Texas, Austin, USA.
Silvia de Lamo CastellviCampus Sescelades, Departament d'Enginyeria Química, Universitat Rovira i Virgili, Tarragona, Spain; Department of Food Science and Technology, The Ohio State University, Columbus, USA.
Lianbo YuCenter of Biostatistics and Bioinformatics, The Ohio State University, Columbus, USA.
Zhanna MikulikDepartment of Internal Medicine, Division of Immunology and Rheumatology, The Ohio State University, USA.
M Monica GiustiDepartment of Food Science and Technology, The Ohio State University, Columbus, USA.
William Michael BrodeDepartment of Internal Medicine, Dell Medical School, The University of Texas, Austin, USA.
Luis Rodriguez-SaonaDepartment of Food Science and Technology, The Ohio State University, Columbus, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundLong COVID (LC/PASC) and Fibromyalgia (FM) share prominent pain, fatigue, and cognitive symptoms and are often difficult to distinguish clinically. The authors compared LC/PASC and FM using harmonized questionnaires assessing symptoms, function, and medication burden to quantify phenotype overlap and inform biomarker development.

methodsThe authors analyzed a harmonized dataset including LC/PASC participants and FM-only comparators. Measures included age, sex, BMI, FIQR/SIQR-equivalent, BDI, CSI, MPQ, VAS pain, medication burden derived from free-text entries, and descriptive SF-36 domains.

resultsThe sample included 54 LC/PASC and 889 FM-only visits. LC/PASC participants were older and less often female. Across symptom and function measures, partial overlap was observed, with domain-specific differences. Medication burden was common; FM showed greater centrally acting medication use. SF-36 domains showed broad similarity with domain-specific differences.

conclusionsIn this preliminary, hypothesis-generating comparison, LC/PASC and FM demonstrate partial and domain-specific overlap across questionnaire measures, while differences in medication exposure may influence symptom reporting and limit direct clinical comparisons. These findings support the need for prospective studies integrating objective biomarkers with standardized clinical phenotyping.

Indexed as

BiomarkersCentrally acting agentsCentral sensitizationFibromyalgiaFIQRLong COVIDMedication burdenPASCSF-36

Identifiers

PMID42398146
PMCPMC13355519

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.